China's Antengene jumps most in 3 months on nod for oncology drug clinical trial

Antengene

02/02/2023 05:19

** Shares of China's oncology medicines developer Antengene
Corporation Ltd  6996.HK  jump as much as 14% to HK$6.28, on
course for the biggest daily pct rise since Nov. 4, 2022
    ** Stock hits the highest since Jan. 16 on the second
session of gain
    ** Shanghai-based biopharmaceutical firm says filing of the
first clinical trial of ATG-022 in patients with advanced or
metastatic solid tumors (CLINCH Trial) has been approved by the
Bellberry Human Research Ethics Committee in Sydney 
    ** Says Clinical Trial Notification has been acknowledged by
the Therapeutic Goods Administration in Australia on Jan. 30 and
the CLINCH Trial is permitted to commence in Australia 
    ** The Hang Seng Commerce & Industry Index  .HSNC  rises
0.8% while the healthcare index  .HSCIH  jump 3.1%
    ** The Hang Seng Composite Index  .HSCI  gains 0.6% and the
Hang Seng Index  .HSI  climbs 0.4%
 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))